Genetic determinants for activated fluoropyrimidine chemotherapy

Drug Development Research

Volumn 67, Issue 2, 2006, Pages 119-129

  Gmeiner, William H ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

5FU; Cancer; Chemotherapy; Fluoropyrimidine; Pharmacogenetics

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; CARBOXYLESTERASE; CYTOSINE DEAMINASE; DEOXYRIBONUCLEOSIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; DNA TOPOISOMERASE; DOXIFLURIDINE; FLOXURIDINE; FLOXURIDINE PHOSPHATE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; METHYLENETETRAHYDROFOLIC ACID; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; OXONATE POTASSIUM; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN P53; RNA; TEGAFUR; THYMIDYLATE SYNTHASE; UNINDEXED DRUG;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DNA DAMAGE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; NONHUMAN; ONCOGENE; PHARMACOGENETICS; PREDICTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT OUTCOME;

EID: 33745191641     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20090     Document Type: Review

References (74)

1. Aschele C, Lonardi S, Monfardini S. 2002. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 28:27-47.
2. Backus HH, van Riel JM, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters, D, Pinedo HM, Peters GJ. 2001. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 12:779-785.
3. Bendardaf R, Lamlum H, Elzagheid A, Ristamaki R, Pyrhonen S. 2005. Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer. Oncol Rep 14:657-662.
4. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263-269.
5. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR. 2004. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gasteroenterology 126:394-401.
6. Cheredame S, Etienne MC, Formento P, Schneider M, Dassonville O, Demard F, Milano G. 1997. Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients. J Clin Oncol 15:2604-2610.
7. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. 2003. Methylenetetrahydrofolate reductasepolymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611-1615.
8. De Angelis PM, Kravik KL, Tunheim SH, Haug T, Reichele WH. 2004. Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols. Mol Cancer 3:1-11.
9. de Bruin M, van Capel T, Van der Born K, Kruyt FA, Fukushima M, Hoekman K, Pinedo HM, Peters GJ. 2003. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 88:957-964.
10. Etienne M-C, Formento J-L, Chazal M, Francoual M, Magne N, Formento P, Bourgeon A, Seitz J-F, Delpero J-R, Letoublon C, Pezet D, Milano G. 2004. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14:785-792.
11. Fang F, Hoskins J, Butler JS. 2004. 5-Fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs. Mol Cell Biol 24:10766-10776.
12. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijmans LAJ, van den Heuvel LP, Rozen RA. 1995. Candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:111-113.
13. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Seitz JF, Labianca R, Chen W, Cha SS, Heidebrandt MP, Goldberg RM. 2004. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and II colon cancer: Who benefits and by how much. J Clin Oncol 22:1797-1806.
14. Gmeiner WH. 2005. Novel chemical strategies for TS inhibition. Curr Med Chem 12:191-202.
15. Gmeiner WH, Trump E, Wei C. 2004. Enhanced DNA-directed effects of FdUMP[10] compared to 5FU. Nucl Nuct Nucl Acids 23:401-410.
16. Grothey A. 2006. Does bavacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy? Nature Clin PractOncol 3:22-23.
17. Hatch SB, Lightfoot HM Jr, Garwacki CP, Moore DT, Calvo BF, Woosley JT, Sciarrotta J, Funkhouser WK, Farber RA. 2005. Microsatellite instability testing in colorectal carcinoma: Choice of markers affects sensitivity of detection of mismatch repair-deficient tumors. Clin Cancer Res 11:2180-2187.
18. Houghton JA, Maroda SJ Jr, Phillips JO, Houghton PJ. 1981. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 41:144-149.
19. Hsiang YH, Lihou MG, Liu LF. 1989. Arrest of replication forks by drug-stabilized topisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
20. Inokuchi M, Uetake H, Shirota Y, Yamada H, Tajima M, Sugihara K. 2004. Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis, Cancer Chemother Pharmacol 53:391-396.
21. Iqbal S, Lenz H-J. 2004. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Future Drugs 4:947-955.
22. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L. 1995. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412.
23. Kakimoto M, Uetake H, Osanai T, Shirota Y, Takagi Y, Takeshita E, Toriya Y, Naenberg K, Danenberg PV, Sugihara K. 2005. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett 223:103-111.
24. Kitajima M, Takita N, Hata M, Maeda T, Sakamoto K, Kamano T, Ochiai T. 2006. The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer. Oncol Rep 15:161-165.
25. Kobayashi H, Koike T, Nakatsuka A, Kurita H, Sagara J, Taniguchi S, Kurashina K. 2005. Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma. Oral Oncol 41:38-47.
26. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG. 1998. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243-1250.
27. Liang J-T, Huang K-C, Cheng Y-M, Hsu H-C, Cheng A-L, Hsu C-H, Yeh K-H, Wang S-M, Chang K-J. 2002. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 97:451-457.
28. Liao Z-Y, Sordet O, Zhang H-L, Kohlhagen G, Antony S, Gmeiner WH, Pommier Y. 2005. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes. Cancer Res 65:4844-4851.
29. Libra M, Navolanic PM, Talamini R, Cecchin E, Sartor F, Tumelo S, Masier S, Travail S, Boiocchi M, Toffoli G. 2005. Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer 4:11-16.
30. Liu C, Willingham M, Liu J, Gmeiner WH. 2002. Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts. Int J Oncol 21:303-308.
31. Liu J, Skradis A, Kolar C, Kolath J, Anderson J, Lawson T, Talmadge J, Gmeiner WH. 1999. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5FU. Nucl Nuct 18:1789-1802.
32. Liu J, Kolar C, Lawson TA, Gmeiner WH. 2001. Targeted drug delivery to chemoresistant cells: Folic acid derivatization of FdUMP[10] enhances cytotoxicity towards human colorectal tumor cells. J Org Chem 66:5655-5663.
33. Longley DB, Harkin DP, Johnston PG. 2003. 5-Fluorouracil: mechanisms of action and clinical strategies. Nature Rev. Cancer 3:330-338.
34. Longley DB, Allen WL, McDermott U, Wilson TR, Latif T, Boyer J, Lynch M, Johnston PG. 2004. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res 10:3562-3571.
35. Marcuello E, Altes A, Menoyo A, Del Rio E, Baiget M. 2005. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 27:1-6.
36. Matsubara N. 2004. Diagnostic application of hMLH1 methylation in hereditary non-polyposis colorectal cancer. Dis Markers 20:277-282.
37. Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ, Johnston PG. 2003. Identification of 5-fluorouracil- inducible target genes using cDNA microarray profiling. Cancer Res 63:4602-4606.
38. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ. 1995. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 14:1-6.
39. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV. 1998. High basal level expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371-2376.
40. Meyers M, Wagner MW, Hwang H-S, Kinsella TJ, Boothman DA. 2001. Role of the hMLH1 DNA mismatch repair protein in fluorpyrimidine-mediated cell death and cell cycle responses. Cancer Res 61:5193-5201.
41. Meyers M, Hwang A, Wagner MW, Bruening AJ, Veigl ML, Sedwick WD, Boothman DA. 2003. A role for DNA mismatch repairin sensing and responding to fluoropyrimidine damage. Oncogene 22:7376-7388.
42. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA. 2005. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 280:5516-5526.
43. Nakagawa T, Tanaka F, Takata T, Matsuoka K, Miyahara R, Otake Y, Yanagihara K, Fukushimab M, Wada H. 2002. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur+Uracil) in patients with p-stage nonsmall-cell lung cancer. J Surg Oncol 81:87-92.
44. Ochiai T, Nishimura K, Noguchi H, Kitajima M, Tsukada A, Watanabe E, Nagaoka I, Futagawa S. 2006. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in respectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 118:3084-3088.
45. Omura K. 2003. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 8:132-138.
46. Ota D, Kusama M, Kaise H, Nakayama S, Misaka T, Tsuchida A, Aoki T. 2004. Evaluation of sensitivity to 5-FU on the basis of thymidylate synthase (TS)/dihydropyrimidine dehydrogenase (DPD) activity and chromosomal analysis in micro tissue specimens of breast cancer. Breast Cancer 11:356-366.
47. Petak I, Tillman DM, Houghton JA. 2000. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res 6:4432-4441.
48. Peters GJ, Backus HHJ, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM. 2002. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587:194-205.
49. Peters GJ, Smorenburg CH, Van Groeningen CJ. 2004. Prospective clinical trials using a pharmacokinetic/pharmacogenomic approach. J Chemother 16(Suppl 4):25-30.
50. Popat S, Hubner R, Houlston RS. 2005. Systemic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618.
51. Poston GJ. 2005. The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol 31:325-330.
52. Pritchard DM, Watson AJM, Potten CS, Jackman AL, Hickman JA. 1997. Inhibition by uridine but not thymine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 94:1795-1799.
53. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ. 2001. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacegenomics J 1:65-70.
54. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ, Zajac-Kaye M. 2004. Thymidylate synthase as an oncogene: A novel role for an essential DNA synthesis enzyme. Cancer Cell 5:341-351.
55. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. 2003. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257.
56. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. 2000. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327.
57. Saw RP, Koorey D, Painter D, Gallagher PJ, Solomon MJ. 2002. p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. Br J Surg 89:1409-1415.
58. Schmitz JC, Chen TM, Chu E. 2004. Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res 64:1431-1435.
59. Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayasizaki Y, Okazaki Y, Danenberg PV, Shimada H. 2005. Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling of cDNA microarrays. Int J Oncol 27:371-376.
60. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, Maeda H, Kido T, Miyoshi S, Matsuda H. 2003. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 104:790-795.
61. Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AMGH, Dercksen W, Pinedo HM, Giaccone G. 2006. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 17:35-42.
62. Sobrero A, Kerr D, Glimelius B, Van Custem E, Milano G, Pritchard DM, Rougier P, Aapro M. 2000. New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 36:559-566.
63. Sohn K-J, Croxford R, Yates Z, Lucock M, Kim Y-I. 2004. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96:134-144.
64. Soong R, Diasio RB. 2005. Advances and challenges in fluorpyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenetics 6:835-847.
65. Takao S, Takebayashi Y, Che X, Shinchi H, Natsugoe S, Miyadera K, Yamada Y, Akiyama S, Aikou T. 1998. Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas. Clin Cancer Res 4:1619-1624.
66. Takebayashi Y, Akiyama S-I, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T. 1996. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110-1117.
67. Tournigand C, de Gramont A. 2006. Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer. Bull Cancer 93(Suppl 1):S11-S15.
68. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne P-L, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A. 2006. OPTOMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer: A GERCOR study. J Clin Oncol 24:394-400.
69. Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J, Carvantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz J-F, Stabuc B, Tujakowski J, Hazel GV, Zaluski J, Scheithauer W. 2005. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704.
70. Uchida K, Hayashi K, Kawakami K, Schneider S, Yochim JM, Kuramochi H, Takasaki K, Danenberg KD, Danenberg PV. 2004. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 10:433-439.
71. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizani C. 2005. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68:171-178.
72. Van Custem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marchall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. 2004. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large randomized, phase III trials. Br J Cancer 90:1190-1197.
73. van Triest B, Pinedo HM, Blaauwgeers JLG, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HFW, Peters GJ. 2000. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6:1063-1072.
74. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y. 2002. Genome-wide cDNAmicroarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62:518-527.